OTLC

Oncotelic Therapeutics, Inc., formerly Mateon Therapeutics, Inc., is an immuno-oncology company. The Company is engaged in development of ribonucleic acid (RNA) therapeutics as well as small molecule drugs against cancer and infectious diseases. The Company’s pipeline includes ArtiVeda/ArtiShield, OT-101, CA4P and Oxi4503. The ArtiVeda/ArtiShield is a derivative from the plant Artemisia. Its immuno-oncology drug candidate, OT-101, is developed for the treatment of solid tumors with focus on brain cancer in adult and diffuse intrinsic pontine glioma (DIPG) in children. The Company’s OT-101 completed phase II for pancreatic cancer, melanoma, and glioblastoma. Its CA4P is a vascular disrupting agent (VDA) in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma. The OXi4503 is developed for the treatment of liquid tumors with focus on childhood leukemia.